PCI Synthesis, a drug substance contract manufacturing organization (CMO) of new chemical entities (NCEs) and generic active pharmaceutical ingredients (APIs), has obtained registration and certification from the U.S. Drug Enforcement Administration (DEA) to handle Schedule II, III, IV and V controlled substances. With DEA registration, the company will be able to work on behalf of clients on projects that are considered controlled substances or the raw materials that are used to produce them...